Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Novel candidate drug for heart failure completes phase I trial

Aug. 30, 2012

Candidate analgesic releases pregabalin and nitric oxide

Aug. 30, 2012

Biomarker has prognostic value in patients with diabetes and coronary artery disease

Aug. 29, 2012

Bristol-Myers Squibb presents in vivo results on new Trk inhibitors

Aug. 29, 2012

Theravance product shows strong antinociceptive activity across a range of pain models

Aug. 29, 2012

Preclinical data support clinical testing of new antiarrhythmic drug

Aug. 29, 2012

Tenascin-C evaluated as a marker of isolated noncompaction cardiomyopathy

Aug. 29, 2012

DNA decoy to prevent postsurgical pain shows promising preclinical toxicity profile

Aug. 29, 2012

New alpha2C-adrenoceptor agonists discovered at Merck & Co.

Aug. 28, 2012

PARAMOUNT study reveals beneficial effects of LCZ-696

Aug. 28, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...